Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis

ClinicalTrials.gov ID: NCT02309359

Public ClinicalTrials.gov record NCT02309359. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 26, 2026, 4:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy

Study identification

NCT ID
NCT02309359
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Ablynx, a Sanofi company
Industry
Enrollment
345 participants

Conditions and interventions

Interventions

  • ALX-0061 Biological
  • Placebo Other
  • Methotrexate Drug

Biological · Other · Drug

Eligibility (public fields only)

Age range
18 Years to 74 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2014
Primary completion
Jul 31, 2016
Completion
Jul 31, 2016
Last update posted
Aug 20, 2019

2015 – 2016

United States locations

U.S. sites
22
U.S. states
12
U.S. cities
21
Facility City State ZIP Site status
Investigator Site Birmingham Alabama 35216
Investigator Site Hemet California 92543
Investigator Site La Palma California 90712
Investigator Site Los Angeles California 90017
Investigator site Los Angeles California 90036
Investigator Site Ventura California 93003
Investigator Sites Hialeah Florida 33016
Investigator Site Homestead Florida 33030
Investigator Site Miami Florida 33135
Investigator Site Miami Lakes Florida 33016
Investigator Site Orlando Florida 32804
Investigator Site Stockbridge Georgia 30281
Investigator Site Overland Park Kansas 66209
Investigator Site Monroe Louisiana 71203
Investigator Site Worcester Massachusetts 01605
Investigator Site Albuquerque New Mexico 87102
Investigator Site Brooklyn New York 11201
Investigator Site New York New York 10018
Investigator Sie Charleston South Carolina 29406
Investigator Site Myrtle Beach South Carolina 29572
Investigator Site Memphis Tennessee 38119
Investigator Site Mesquite Texas 75150

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 72 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02309359, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 20, 2019 · Synced Jun 26, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02309359 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →